Publication:
What are the main barriers to achieve minimal disease activity in psoriatic arthritis in real life?

dc.contributor.authorsBakirci, S.; Solmaz, D.; Al Osaimi, N.; Dalkilic, E.; Can, M.; Erden, A.; Ozisler, C.; Cinar, M.; Kilic, L.; Kucuk, A.; Omma, A.; Yildiz, F.; Dogru, A.; Tufan, A.; Esmen, S. E.; Akar, S.; Kalyoncu, U.; Aydin, S. Z.
dc.date.accessioned2022-03-12T22:39:33Z
dc.date.accessioned2026-01-10T19:52:09Z
dc.date.available2022-03-12T22:39:33Z
dc.date.issued2019
dc.description.abstractObjective Minimal disease activity (MDA) is an important target in patients with psoriatic arthritis (PsA), however it is also criticised for having a low threshold for patient reported outcomes (PRO). The aim of the study was to assess the prevalence of MDA and its components in patients with PsA and to evaluate disease characteristics and patterns in patients with or without MDA (MDA(+) or MDA(-)). Methods PsArt-ID (Psoriatic Arthritis-International Database) is a prospective, multicentre web-based registry. PsA patients who had at least 1 year of disease duration and had full data for MDA were included for this analysis (n=317). Patients were considered in MDA+ when they met at least 5/7 of the MDA criteria. Results MDA was achieved in 46% patients. Within MDA- patients, body surface area (51.2%) and swollen joint count (53.5%) domains could still be achieved in the majority and 93.5% of them had no enthesitis using the Leeds enthesitis index. Of 170 patients with MDA-, 90 patients did not fulfill all 3 PROs of MDA. Mono-arthritis subtype (RR: 2.01), absence of enthesitis (RR: 1.570) and absence of distal interphalangeal (DIP) joint disease (RR: 1.1) were associated with higher probability of achieving MDA. Conclusion The MDA criteria provide an objective target for treatment in trials and clinical practice; however, in real life PROs are the most significant barriers to achieve MDA. The presence of DIP joints disease makes it difficult to reach MDA due to active PROs.
dc.identifier.doidoiWOS:000485817300014
dc.identifier.eissn1593-098X
dc.identifier.issn0392-856X
dc.identifier.pubmed30767863
dc.identifier.urihttps://hdl.handle.net/11424/235846
dc.identifier.wosWOS:000485817300014
dc.language.isoeng
dc.publisherCLINICAL & EXPER RHEUMATOLOGY
dc.relation.ispartofCLINICAL AND EXPERIMENTAL RHEUMATOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectpsoriatic arthritis
dc.subjectminimal disease activity
dc.subjectpatient-reported outcomes
dc.subjectPREDICTORS
dc.subjectCRITERIA
dc.titleWhat are the main barriers to achieve minimal disease activity in psoriatic arthritis in real life?
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage812
oaire.citation.issue5
oaire.citation.startPage808
oaire.citation.titleCLINICAL AND EXPERIMENTAL RHEUMATOLOGY
oaire.citation.volume37

Files